Research programme: antibody-drug conjugates - Genentech

Drug Profile

Research programme: antibody-drug conjugates - Genentech

Alternative Names: 11D10.1.14; 11D10.1.14 ADC; 11D10.1.14-auristatin conjugate; 3A5-VC-MMAE; 3A5-VC-MMAF; 3A5-VC-monomethylauristatin-E; 3A5-VC-monomethylauristatin-F; Anti-CA-125 ADC; Anti-CA-125 antibody drug conjugate; Anti-MUC16 ADC; Drug-conjugated 11D10; Drug-conjugated 3A5

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Developer Genentech; Seattle Genetics
  • Class Auristatins; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 03 Aug 2010 Seattle Genetics and Genentech expand their antibody-drug conjugate collaborative agreement
  • 21 Apr 2010 Seattle Genetics and Genentech extend their original antibody-drug conjugate collaborative agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top